可切除边缘性胰腺癌的新辅助治疗
Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.
作者信息
Barreto Savio George, Shrikhande Shailesh V, Sirohi Bhawna
机构信息
Division of Surgery and Perioperative Medicine, Flinders Medical Centre, Bedford Park, Adelaide, South Australia Australia.
College of Medicine and Public Health, Flinders University, Adelaide, South Australia Australia.
出版信息
Indian J Surg Oncol. 2024 May;15(Suppl 2):249-254. doi: 10.1007/s13193-021-01361-1. Epub 2021 Jul 1.
Abstract
In this perspective, we present our assessment of all of the known accumulated evidence on the role of neoadjuvant therapy in the management of borderline resectable pancreatic cancer highlighting the gaps in the data, the current regimens used and providing a brief insight into the way forward.
摘要
从这个角度出发，我们对新辅助治疗在临界可切除胰腺癌管理中的作用的所有已知累积证据进行评估，突出数据中的差距、目前使用的治疗方案，并简要展望未来的方向。
相似文献
1
Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer.
Indian J Surg Oncol. 2024 May;15(Suppl 2):249-254. doi: 10.1007/s13193-021-01361-1. Epub 2021 Jul 1.
2
The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
Am Surg. 2024 Nov;90(11):3061-3073. doi: 10.1177/00031348241248703. Epub 2024 Apr 18.
3
Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.
4
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z.
5
Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program.
Surg Open Sci. 2020 Jul 29;2(4):25-31. doi: 10.1016/j.sopen.2020.07.003. eCollection 2020 Oct.
6
Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zrae172.
7
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
8
How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Eur Radiol. 2022 Jan;32(1):56-66. doi: 10.1007/s00330-021-08108-0. Epub 2021 Jun 25.
9
Borderline resectable pancreatic cancer: on the edge of survival.
Cancer Control. 2008 Oct;15(4):295-307. doi: 10.1177/107327480801500404.
10
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Dig Surg. 2019;36(6):455-461. doi: 10.1159/000493466. Epub 2018 Nov 8.
本文引用的文献
1
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Ann Surg. 2020 Sep 1;272(3):481-486. doi: 10.1097/SLA.0000000000004155.
2
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.
3
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073.
4
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Ann Surg. 2021 Feb 1;273(2):341-349. doi: 10.1097/SLA.0000000000003284.
5
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Ann Surg. 2021 Mar 1;273(3):579-586. doi: 10.1097/SLA.0000000000003301.
6
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Radiat Oncol. 2019 Mar 27;14(1):52. doi: 10.1186/s13014-019-1254-8.
7
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
8
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
9
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.
Ann Surg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018 Oct 25.
10
Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
J Gastrointest Surg. 2019 Jan;23(1):112-121. doi: 10.1007/s11605-018-3966-8. Epub 2018 Sep 21.
Zotero 插件